Breast Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Women who have invasive breast cancer in one breast only, with cancer that has spread to nearby lymph nodes in the armpit (rated cN1 to cN3 on medical staging).
- People whose lymph node involvement has been confirmed through a biopsy or similar test.
- People who are planned to receive chemotherapy before surgery (sometimes combined with immunotherapy), followed by assessment and treatment of the breast and armpit area.
Who may not be able to join:
- People whose lymph nodes showed no signs of cancer before starting chemotherapy treatment.
- People who have invasive breast cancer in both breasts.
- People who are planned to receive hormone-based therapy before surgery (rather than chemotherapy).
- People who have cancer that has spread to other parts of the body beyond the breast and nearby lymph nodes, including small numbers of distant spread (called oligometastatic disease).
- People who have had invasive breast cancer in the past.
- People who have, or have had, other types of cancer — with the exception of certain skin cancers (basal cell or squamous cell) or non-invasive cancer of the cervix or breast.
- People who have already had surgery or radiation therapy to the armpit area before starting chemotherapy, including a procedure called sentinel lymph node biopsy.
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Marjolein Smidt, MD, PhD, Maastricht University Medical Center
Phone: +31433881574
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Disease free survival (DFS); Breast cancer specific survival (BCSS); Overall survival (OS); Axillary recurrence rate (ARR); Quality of life, as measured by EQ-5D-5L; Quality of life, as measured by Quality of Life Questionnaire Core 30 Items (QLQ-C30) and QLQ-BR23; Quality of life, as measured by BREAST-Q, which includes the following domains: satisfaction with breasts, psychosocial well being, physical well being, sexual well being.
Can't join this trial?
Data last synced from ClinicalTrials.gov: 7 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.